News articles about GlycoMimetics (NASDAQ:GLYC) have been trending somewhat positive this week, according to Alpha One Sentiment. Alpha One, a division of Accern, identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlycoMimetics earned a daily sentiment score of 0.14 on Alpha One’s scale. Alpha One also assigned news articles about the biotechnology company an impact score of 37 out of 100, meaning that recent media coverage is unlikely to have an effect on the company’s share price in the near future.

These are some of the media stories that may have impacted Alpha One Sentiment’s scoring:

Several research analysts have recently issued reports on GLYC shares. Canaccord Genuity reissued a “buy” rating and issued a $12.00 target price on shares of GlycoMimetics in a research report on Friday. Zacks Investment Research upgraded GlycoMimetics from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Tuesday, May 2nd. Finally, Cowen and Company restated a “buy” rating on shares of GlycoMimetics in a research note on Tuesday, May 9th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $11.94.

Shares of GlycoMimetics (NASDAQ:GLYC) traded up 19.59% during mid-day trading on Friday, reaching $12.76. The company’s stock had a trading volume of 36,171,881 shares. GlycoMimetics has a one year low of $3.82 and a one year high of $14.64. The firm’s market cap is $314.41 million. The firm’s 50 day moving average is $4.92 and its 200 day moving average is $5.85.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.03. On average, equities analysts anticipate that GlycoMimetics will post ($1.41) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/05/20/glycomimetics-glyc-receives-daily-coverage-optimism-rating-of-0-14-updated.html.

GlycoMimetics Company Profile

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

12 Month Chart for NASDAQ:GLYC

Receive News & Stock Ratings for GlycoMimetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc and related stocks with our FREE daily email newsletter.